QKY-613 is a prodrug designed to enhance immune surveillance by targeting nucleic acid modification pathways. It selectively facilitates the incorporation of 6mdA (N6-methyl-deoxyadenosine) into viral DNA, boosting the DNA's phase separation potential and subsequently increasing cGAS activation levels to strengthen host immune surveillance. In mouse models of viral infection, QKY-613 significantly reduced mortality in aged mice. This compound holds promise for studying immune surveillance mechanisms based on nucleic acid modifications.